Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Study crawled date : 2022 - 11 - 03 save search
Shuttle Pharmaceuticals Engages Theradex Oncology in Preparation for Clinical Study
Published: 2022-11-03 (Crawled : 20:00) - biospace.com/
SHPH | $0.4014 110
|
|
| O: 0.87%
H: 2.16%
C: -4.31%
pharmaceuticals study
Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin’s Lymphoma at the American Society of Hematology Annual Meeting
Published: 2022-11-03 (Crawled : 14:00) - biospace.com/
XNCR | $18.95 -0.63% -0.47% 0
|
Health Technology
|
| O: -0.84%
H: 1.99%
C: -0.4%
meeting study phase 1
Alpine Immune Sciences to Present ALPN-303 Phase 1 (RUBY-1) Study Data at 2022 American Society of Hematology Annual Meeting & Exposition
Published: 2022-11-03 (Crawled : 14:00) - biospace.com/
ALPN | $64.43 -0.05% -0.02% 21
|
Health Technology
|
| O: -0.17%
H: 9.68%
C: 7.68%
alpn-303 sciences meeting study phase 1
Orchard Therapeutics Announces First Neurocognitive Data from OTL-201 Study in MPS-IIIA Accepted for Oral Presentation at ASH 2022
Published: 2022-11-03 (Crawled : 14:00) - globenewswire.com
ORTX | $16.7 0.0% 370K
|
Health Technology
|
| O: -0.36%
H: 2.68%
C: -0.18%
otl-201 therapeutics presentation study
Prothena to Present Data on Survival Benefit Observed in Completed Phase 3 Study of Drug Candidate Birtamimab in Patients with Mayo Stage IV AL Amyloidosis at the ASH 2022 Meeting
Published: 2022-11-03 (Crawled : 14:00) - biospace.com/
PRTA 4 | $20.57 -2.05% -1.94% 0
|
Health Technology
|
| O: -1.99%
H: 0.55%
C: -1.64%
drug candidate meeting study
IN8bio to Present Positive Early Data from Ongoing Phase 1 Study of INB-100 at the 64th American Society of Hematology Annual Meeting
Published: 2022-11-03 (Crawled : 13:00) - globenewswire.com
INAB | $1.05 24K
|
|
| O: -10.75%
H: 19.82%
C: 12.89%
inb-100 ongoing meeting positive study phase 1
Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at HSG 2022
Published: 2022-11-03 (Crawled : 13:00) - biospace.com/
NBIX M | $132.54 -0.52% -0.56% 8
|
Health Technology
|
| O: -0.09%
H: 2.71%
C: 1.77%
huntington disease study huntington’s disease
Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting
Published: 2022-11-03 (Crawled : 13:00) - globenewswire.com
CNTA | $10.53 -2.32% -1.99% 50
|
Manufacturing
|
| O: -0.97%
H: 0.0%
C: -2.7%
treatment pharmaceuticals extension study phase 2b
Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints Met in Pivotal Phase 3 VIITAL™ Study of EB-101
Published: 2022-11-03 (Crawled : 12:20) - biospace.com/
ABEO | $7.53 -5.04% -5.03% 12
|
Health Technology
|
| O: 0.9%
H: 2.22%
C: -14.0%
eb-101 topline therapeutics positive results study
Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Association for the Study of Liver Diseases (AASLD) 2022 Liver Meeting
Published: 2022-11-03 (Crawled : 11:00) - prnewswire.com
MNK | $0.3402 -0.06% 540K
|
n/a
|
| O: -1.02%
H: 3.45%
C: 3.1%
terlivaz liver meeting injection study
Foam Blowing Agents Market to Gain Value of US$ 2.9 Bn by 2031: TMR Study
Published: 2022-11-03 (Crawled : 09:00) - prnewswire.com
HON | News M | $191.08 0.38% 0.41% 840
|
Producer Manufacturing
|
| O: -0.05%
H: 2.83%
C: 2.01%
study market
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
AGBA | News | $1.4 250.0% 35M
|
Finance
RWOD | $12.0 50.06% 3.9M
|
n/a
INDO | $4.9 20.1% 2.2M
|
Energy Minerals
NURO | $4.32 18.36% 66K
|
Health Technology
HUBC | $1.52 17.83% 4.7M
|
n/a
CARV 4 | $1.77 11.32% 8.5K
|
Finance
BROG | $1.23 10.81% 320K
|
Finance
PARA | $12.03 9.66% 5.8M
|
Information
ADAP | $0.98 9.08% 240K
|
Health Technology
POAI A | $1.25 8.69% 16K
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.